Named Patient Program

Allows physicians and their patients to access drugs which have not yet received approval for marketing by concerned health authorities of the country. Governments worldwide have created provisions for granting access to drugs prior to approval for patients who have exhausted all alternative treatment options and do not match clinical trial entry criteria, Often grouped under the labels of compassionate use, expanded access criteria, data collection, promotion, and control of drug distribution.

Program can speed uptake after official launch. Physicians, who have had experience before launch, via clinical trials or named patient programs, often become early adopters and references for other physicians once the drug is freely circulating .

Yervoy (Ipilimumab-BMS) Vial Medicine for Chemotherapy Medication

Zelboraf Medicine for Chemotherapy Medication

Dabrafenib (Tafinlar GSK) 50mg Capsules

Mekinist (Trametinib GSK) 2mg Capsules

Keytruda 50 mg/vial

Opdivo (nivolumab) injection



Teysuno 15mg/5.8mg/15.8mg.

zykadia 150 mg

ZALTRAP Medicine